Does ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Cause Off label use? 73 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 73 reports of Off label use have been filed in association with ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT. This represents 0.7% of all adverse event reports for ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT.
73
Reports of Off label use with ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT
0.7%
of all ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT reports
3
Deaths
16
Hospitalizations
How Dangerous Is Off label use From ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT?
Of the 73 reports, 3 (4.1%) resulted in death, 16 (21.9%) required hospitalization, and 5 (6.8%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT. However, 73 reports have been filed with the FAERS database.
What Other Side Effects Does ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Cause?
Haemarthrosis (3,360)
Haemorrhage (2,925)
Fall (709)
Arthralgia (561)
Muscle haemorrhage (554)
Limb injury (525)
Drug ineffective (513)
Joint injury (511)
Contusion (496)
Pain (484)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Alternatives Have Lower Off label use Risk?
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT RESIDUES 743-1636 DELETED
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs ANTIHEMOPHILIC FACTOR, PEGYLATED HUMAN SEQUENCE RECOMBINANT
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs ANTIHEMOPHILIC FACTOR PORCINE, B-DOMAIN TRUNCATED RECOMBINANT
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APALUTAMIDE
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APATINIB